What are Antineoplastic agents drugs?

Antineoplastic agents drugs are pharmacologic agents that share a common mechanism (typically targeting EGFR). 0 are currently marketed, with 8 more in clinical development.

Antineoplastic agents

0 marketed 3 in Phase 3 4 in Phase 2 1 in Phase 1

This page covers all Antineoplastic agents drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting EGFR, Thymidylate synthase, DNA, Thymidylate synthase.

Targets

EGFR · Thymidylate synthase, DNA · Thymidylate synthase · EGFR, VEGFR · EGFR, thymidylate synthase · Topoisomerase I, Topoisomerase II

Phase 3 pipeline (3)

cetuximab + cisplatin + vinorelbine · Merck KGaA, Darmstadt, Germany · Oncology
Cetuximab targets the epidermal growth factor receptor (EGFR), while cisplatin and vinorelbine work by interfering with DNA replication and cell division.
cytarabine and mitoxantrone · Pfizer · Oncology
Cytarabine is a nucleoside analog that interferes with DNA synthesis, while mitoxantrone is a topoisomerase II inhibitor that disrupts DNA replication and transcription.
S-1 plus Cisplatin · Taiho Pharmaceutical Co., Ltd. · Oncology
S-1 is a fluoropyrimidine derivative that inhibits thymidylate synthase, while cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription.

Phase 2 pipeline (4)

Capecitabine and Mitomycin C · Croatian Cooperative Group for Clinical Research in Oncology · Oncology
Capecitabine is a thymidylate synthase inhibitor, and Mitomycin C is an alkylating agent.
Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan · Central European Cooperative Oncology Group · Oncology
Inhibits epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinases.
Carbo, 5FU, Cetuximab · Groupe Oncologie Radiotherapie Tete et Cou · Oncology
Carbo, 5FU, and Cetuximab work together to inhibit DNA synthesis and induce apoptosis in rapidly dividing cancer cells.
Capecitabine, Oxaliplatin, Cetuximab · Asan Medical Center · Oncology
Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells. Oxaliplatin is a platinum-based chemotherapy drug that works by cross-linking DNA in cancer cells, thereby inhibiting their replication. Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), blocking its activation and subsequent signaling pathways that promote cancer cell growth.

Phase 1 pipeline (1)

ALIMTA plus Epirubicin · Eli Lilly and Company · Oncology
Topoisomerase I inhibitor